Impact of Vitamin D on Therapeutic Respons in NPC Chemoradiated Patients

Nasopharyngeal cancer is the sixth most common cancer and the sixth leading cause of death in Indonesia. NPC is a radiosensitive cancer so radiotherapy is the basic therapy for NPC. Concurrent chemoradiotherapy (CCRT) with Intensity modulated radiotherapy (IMRT) is the standard therapy for locally advanced NPC. Vitamin D deficiency is common in patients with head and neck cancer including NPC. Several studies have shown better outcomes and fewer complications of therapy in patients with higher vitamin D levels. Inflammation plays an important role in tumor development and progression. The effect of vitamin D supplementation on cancerous and precancerous lesions shows that there is a potential for major changes in IL-6 levels. By supplementing vitamin D in NPC patients with vitamin D deficiency before undergoing chemoradiation, it will increase the therapeutic response and reduce IL-6 levels (proinflammatory cytokines). Until now, there have been no studies evaluating the administration of vitamin D supplementation in NPC patients with vitamin D deficiency undergoing chemoradiation in Indonesia.

NCT Number	NCT07042711
Lead Sponsor	Indonesia University
Conditions	Nasopharyngeal Cancinoma (NPC)
Enrollment	300 participants
Start Date	2025-01-10
Primary Completion	2025-12-09 (estimated)
Study Completion	2025-12-09 (estimated)
Updated on ClinicalTrials.gov	2025-06-29